This paper evaluates the state of continuous subcutaneous insulin infusion (CSII) in Italy as of April 2005. We used a questionnaire covering clinical, technical and organisational aspects of CSII. We found that there were 2702 patients on CSII,97% with type 1 diabetes. Of them 20% started CSII before the age of 19, 97% used more than one basal insulin infusion rate, 95% used a rapid-acting insulin analog and 98% used teflon needles. The main goal of CSII was to improve metabolic control. A better metabolic control was perceived as the main advantage by most physicians, while the high cost was considered as an important burden. Fifty-seven per cent of centres started CSII on outpatients. Twenty-four hours assistance was guaranteed in 72% of centres. CSII in Italy is increasing. © 2006 Elsevier Ireland Ltd. All rights reserved.
Bruttomesso, D., Costa, S., Crazzolara, D., Di Bartolo, P., Girelli, A., Tiengo, A., et al. (2006). Continuous subcutaneous insulin infusion (CSII) in Italy. DIABETES RESEARCH AND CLINICAL PRACTICE, 74(2), 130-134 [10.1016/S0168-8227(06)70016-X].
Continuous subcutaneous insulin infusion (CSII) in Italy
Di Bartolo P.;Tiengo A.;
2006
Abstract
This paper evaluates the state of continuous subcutaneous insulin infusion (CSII) in Italy as of April 2005. We used a questionnaire covering clinical, technical and organisational aspects of CSII. We found that there were 2702 patients on CSII,97% with type 1 diabetes. Of them 20% started CSII before the age of 19, 97% used more than one basal insulin infusion rate, 95% used a rapid-acting insulin analog and 98% used teflon needles. The main goal of CSII was to improve metabolic control. A better metabolic control was perceived as the main advantage by most physicians, while the high cost was considered as an important burden. Fifty-seven per cent of centres started CSII on outpatients. Twenty-four hours assistance was guaranteed in 72% of centres. CSII in Italy is increasing. © 2006 Elsevier Ireland Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
